Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers

Figure 2 Intra-individual comparison of therapeutic responses to combretastatin-A4-phosphate between a primary hepatocellular carcinoma and a hepatic R1 allograft located in different liver lobes. A: T2WIs (1-1’’), T1WIs (2-2’) and CE-T1WIs (3-3’’) of an implanted R1-tumor (green arrows) and a primary HCC (orange arrows) located in the median and left liver lobes, respectively, at baseline and 1 h and 12 h after CA4P therapy; B: Corresponding photomacrographs of median and left liver lobes (top panels), photomacrograph of liver blocks (middle panel) in 2-mm thickness corresponding to the transversal MRI, and microangiogram (bottom panel) of tumor-bearing liver blocks, revealing one R1-tumor (green circle) and one primary HCC (orange circle); C: Corresponding photomicrographs of R1-tumor (left column) and primary HCC (right column) in the median and left lobes, respectively. (HE staining; upper panels, × 12.5 original magnification, scale bar = 800 μm; lower panels, × 100 original magnification, scale bar = 100 μm, × 400 original magnification, scale bar = 25 μm); D: Sham control: T2WIs (1, 1’), T1WIs (2, 2’) and CE-T1WIs (3, 3’) of R1-tumor (green arrows) and primary HCC (orange arrows) located in the median and left liver lobes, respectively, at 12 h post PBS treatment, and corresponding photomicrographs (4, 4’; HE staining × 100 original magnification, scale bar = 100 μm, × 400 original magnification, scale bar = 25 μm). HCC: Hepatocellular carcinoma; L: Liver; N: Tumoral necrosis; PBS: Phosphate-buffered saline; T: Viable tumor.